[1] Chen Dongying,Wang Wuliang.Clinical efficacy analysis of peritoneal heat perfusion combined with intravenous chemotherapy in patients after ovarian cancer [J]. The Electronic Journal of Modern Medicine and Health Research, 2022,6 (18): 68-71.[2] Kitayama J, Ishigami H, Yamaguchi H and Watanabe T: Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) combined with oral tegafur/gimeracil/oteracil potassium (S-1) for gastric cancer with peritoneal metastasis. Eur J Surg Oncol 40: S34, 2014.[3] Ceelen W, Braet H, van Ramshorst G, Willaert W, Remaut K. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion.Expert Opin Drug Deliv. 2020;17(4):511-522. doi:10.1080/17425247.2020.1736551[4] Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 2012;21(4):645-663. doi:10.1016/j.soc.2012.07.007[5] van den Tempel N, Horsman MR, Kanaar R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int J Hyperthermia. 2016;32(4):446-454. doi:10.3109/02656736. 2016.1157216[6] Didelot C, Lanneau D, Brunet M, et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins.Curr Med Chem. 2007;14(27):2839-2847. doi:10.2174/092986707782360079[7] Zunino B, Rubio-Patiño C, Villa E, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016;35(2):261-268. doi:10.1038/onc.2015.82[8] Mallory M, Gogineni E, Jones GC, Greer L, Simone CB 2nd. Therapeutic hyperthermia: The old, the new, and the upcoming. Crit Rev Oncol Hematol. 2016;97:56-64. doi:10.1016/j.critrevonc.2015.08.003
